Saflufenacil; Pesticide Tolerances, 27256-27261 [2011-11553]
Download as PDF
27256
Federal Register / Vol. 76, No. 91 / Wednesday, May 11, 2011 / Rules and Regulations
I. General Information
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2010–0755; FRL–8872–7]
Saflufenacil; Pesticide Tolerances
Environmental Protection
Agency (EPA).
AGENCY:
ACTION:
Final rule.
This regulation revises or
removes certain established tolerances
and establishes new tolerances for
residues of saflufenacil in or on
multiple commodities which are
identified and discussed later in this
document. BASF Corporation requested
these tolerances under the Federal Food,
Drug, and Cosmetic Act (FFDCA).
SUMMARY:
This regulation is effective May
11, 2011. Objections and requests for
hearings must be received on or before
July 11, 2011, and must be filed in
accordance with the instructions
provided in 40 CFR part 178 (see also
Unit I.C. of the SUPPLEMENTARY
INFORMATION).
DATES:
EPA has established a
docket for this action under docket
identification (ID) number EPA–HQ–
OPP–2010–0755. All documents in the
docket are listed in the docket index
available at https://www.regulations.gov.
Although listed in the index, some
information is not publicly available,
e.g., Confidential Business Information
(CBI) or other information whose
disclosure is restricted by statute.
Certain other material, such as
copyrighted material, is not placed on
the Internet and will be publicly
available only in hard copy form.
Publicly available docket materials are
available in the electronic docket at
https://www.regulations.gov, or, if only
available in hard copy, at the OPP
Regulatory Public Docket in Rm. S–
4400, One Potomac Yard (South Bldg.),
2777 S. Crystal Dr., Arlington, VA. The
Docket Facility is open from 8:30 a.m.
to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket
Facility telephone number is (703) 305–
5805.
ADDRESSES:
srobinson on DSKHWCL6B1PROD with RULES
FOR FURTHER INFORMATION CONTACT:
Susan Stanton, Registration Division
(7505P), Office of Pesticide Programs,
Environmental Protection Agency, 1200
Pennsylvania Ave., NW., Washington,
DC 20460–0001; telephone number:
(703) 305–5218; e-mail address:
stanton.susan@epa.gov.
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
16:21 May 10, 2011
Jkt 223001
A. Does this action apply to me?
You may be potentially affected by
this action if you are an agricultural
producer, food manufacturer, or
pesticide manufacturer. Potentially
affected entities may include, but are
not limited to those engaged in the
following activities:
• Crop production (NAICS code 111).
• Animal production (NAICS code
112).
• Food manufacturing (NAICS code
311).
• Pesticide manufacturing (NAICS
code 32532).
This listing is not intended to be
exhaustive, but rather to provide a guide
for readers regarding entities likely to be
affected by this action. Other types of
entities not listed in this unit could also
be affected. The North American
Industrial Classification System
(NAICS) codes have been provided to
assist you and others in determining
whether this action might apply to
certain entities. If you have any
questions regarding the applicability of
this action to a particular entity, consult
the person listed under FOR FURTHER
INFORMATION CONTACT.
B. How can I get electronic access to
other related information?
You may access a frequently updated
electronic version of EPA’s tolerance
regulations at 40 CFR part 180 through
the Government Printing Office’s e-CFR
site at https://www.gpoaccess.gov/ecfr.
C. How can I file an objection or hearing
request?
Under FFDCA section 408(g), 21
U.S.C. 346a, any person may file an
objection to any aspect of this regulation
and may also request a hearing on those
objections. You must file your objection
or request a hearing on this regulation
in accordance with the instructions
provided in 40 CFR part 178. To ensure
proper receipt by EPA, you must
identify docket ID number EPA–HQ–
OPP–2010–0755 in the subject line on
the first page of your submission. All
objections and requests for a hearing
must be in writing, and must be
received by the Hearing Clerk on or
before July 11, 2011. Addresses for mail
and hand delivery of objections and
hearing requests are provided in 40 CFR
178.25(b).
In addition to filing an objection or
hearing request with the Hearing Clerk
as described in 40 CFR part 178, please
submit a copy of the filing that does not
contain any CBI for inclusion in the
public docket. Information not marked
confidential pursuant to 40 CFR part 2
PO 00000
Frm 00038
Fmt 4700
Sfmt 4700
may be disclosed publicly by EPA
without prior notice. Submit a copy of
your non-CBI objection or hearing
request, identified by docket ID number
EPA–HQ–OPP–2010–0755, by one of
the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the on-line
instructions for submitting comments.
• Mail: Office of Pesticide Programs
(OPP) Regulatory Public Docket (7502P),
Environmental Protection Agency, 1200
Pennsylvania Ave., NW., Washington,
DC 20460–0001.
• Delivery: OPP Regulatory Public
Docket (7502P), Environmental
Protection Agency, Rm. S–4400, One
Potomac Yard (South Bldg.), 2777 S.
Crystal Dr., Arlington, VA. Deliveries
are only accepted during the Docket
Facility’s normal hours of operation
(8:30 a.m. to 4 p.m., Monday through
Friday, excluding legal holidays).
Special arrangements should be made
for deliveries of boxed information. The
Docket Facility telephone number is
(703) 305–5805.
II. Summary of Petitioned-For
Tolerance
In the Federal Register of September
23, 2010 (75 FR 57942) (FRL–8845–4),
EPA issued a notice pursuant to section
408(d)(3) of FFDCA, 21 U.S.C.
346a(d)(3), announcing the filing of
pesticide petitions (PP 0F7744 and PP
0F7766) by BASF Corporation, 26 Davis
Drive, P.O. Box 13528, Research
Triangle Park, NC 27709–3528. The
petitions requested that 40 CFR 180.649
be amended by establishing tolerances
for residues of the herbicide
saflufenacil, 2-chloro-5-[3,6-dihydro-3methyl-2,6-dioxo-4-(trifluoromethyl)-1(2
H)-pyrimidinyl]-4-fluoro- N-[[methyl(1methylethyl)amino]sulfonyl]benzamide,
and its metabolites N-[2-chloro-5-(2,6dioxo-4-(trifluoromethyl)-3,6-dihydro1(2 H)-pyrimidinyl)-4-fluorobenzoyl]N-′isopropylsulfamide and N-[4-chloro2-fluoro-5-({[(isopropylamino)
sulfonyl]amino}carbonyl)phenyl]urea,
calculated as the stoichiometric
equivalent of saflufenacil, in or on
oilseeds, cottonseed subgroup 20C, gin
byproducts at 3.5 parts per million
(ppm); oilseeds, cottonseed subgroup
20C, undelinted seed at 0.2 ppm;
oilseeds, sunflower subgroup 20B, seed
at 1.0 ppm; pea, vines at 8.0 ppm;
soybean, aspirated grain fractions at
4.52 ppm; soybean, hulls at 0.42 ppm;
soybean, seed at 0.1 ppm; vegetable,
legume, subgroup 6C, beans, dry at 0.5
ppm; and vegetable, legume, subgroup
6C, peas, dry at 0.1 ppm (PP 0F7744);
and in or on oilseeds, rapeseed
subgroup 20A, seed at 0.8 ppm (PP
0F7766). That notice referenced
E:\FR\FM\11MYR1.SGM
11MYR1
Federal Register / Vol. 76, No. 91 / Wednesday, May 11, 2011 / Rules and Regulations
summaries of the petitions prepared by
BASF Corporation, the registrant, which
are available in the docket, https://
www.regulations.gov. There were no
comments received in response to the
notice of filing.
Based upon review of the data
supporting the petition, EPA has revised
the proposed commodity terms and
tolerance levels for several commodities
and determined that established
tolerances for certain livestock
commodities should be increased. The
reasons for these changes are explained
in Unit IV.C.
III. Aggregate Risk Assessment and
Determination of Safety
Section 408(b)(2)(A)(i) of FFDCA
allows EPA to establish a tolerance (the
legal limit for a pesticide chemical
residue in or on a food) only if EPA
determines that the tolerance is ‘‘safe.’’
Section 408(b)(2)(A)(ii) of FFDCA
defines ‘‘safe’’ to mean that ‘‘there is a
reasonable certainty that no harm will
result from aggregate exposure to the
pesticide chemical residue, including
all anticipated dietary exposures and all
other exposures for which there is
reliable information.’’ This includes
exposure through drinking water and in
residential settings, but does not include
occupational exposure. Section
408(b)(2)(C) of FFDCA requires EPA to
give special consideration to exposure
of infants and children to the pesticide
chemical residue in establishing a
tolerance and to ‘‘ensure that there is a
reasonable certainty that no harm will
result to infants and children from
aggregate exposure to the pesticide
chemical residue.’’
Consistent with section 408(b)(2)(D)
of FFDCA, and the factors specified in
section 408(b)(2)(D) of FFDCA, EPA has
reviewed the available scientific data
and other relevant information in
support of this action. EPA has
sufficient data to assess the hazards of
and to make a determination on
aggregate exposure for saflufenacil
including exposure resulting from the
tolerances established by this action.
EPA’s assessment of exposures and risks
associated with saflufenacil follows.
srobinson on DSKHWCL6B1PROD with RULES
A. Toxicological Profile
EPA has evaluated the available
toxicity data and considered its validity,
completeness, and reliability as well as
the relationship of the results of the
studies to human risk. EPA has also
considered available information
concerning the variability of the
sensitivities of major identifiable
subgroups of consumers, including
infants and children.
VerDate Mar<15>2010
16:21 May 10, 2011
Jkt 223001
Saflufenacil has low acute toxicity via
the oral, dermal, and inhalation routes
of exposure. It is slightly irritating to the
eye but is neither a dermal irritant nor
sensitizer.
Short-term, subchronic, and chronic
toxicity studies in rats, mice, and dogs
identified the hematopoietic system as
the target organ of saflufenacil.
Protoporphyrinogen oxidase inhibition
in the mammalian species may result in
disruption of heme synthesis which in
turn causes anemia. In these studies,
decreased hematological parameters
[red blood cells (RBC), hematocrit (Ht),
mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), and
mean corpuscular hemoglobin
concentration (MCHC)] were seen at
about the same dose level across
species, except in the case of the dog,
where the effects were seen at a slightly
higher dose. These effects occurred
around the same dose level from the
short- through long-term exposures
without increasing in severity. Effects
were also seen in the liver (increased
weight, centrilobular fatty change, and
lymphoid infiltrate) in mice, the spleen
(increased spleen weight and
extramedullary hematopoiesis) in rats,
and in both these organs (increased iron
storage in the liver and extramedullary
hematopoiesis in the spleen) in dogs. No
dermal toxicity was seen at the limit
dose in a 28-day dermal toxicity study
in rats.
Carcinogenicity studies in rats and
mice showed no evidence of increased
incidence of tumors at the tested doses.
Saflufenacil is weakly clastogenic in the
in vitro chromosomal aberration assay
in V79 cells in the presence of S9
activation; however, the response was
not evident in the absence of S9
activation. It is neither mutagenic in
bacterial cells nor clastogenic in rodents
in vivo. Saflufenacil is classified as ‘‘not
likely to be carcinogenic to humans.’’
Increased fetal and offspring
susceptibility to saflufenacil were
observed in the developmental toxicity
studies in the rat and rabbit and in the
2-generation reproduction study in the
rat. Developmental effects such as
decreased fetal body weights and
increased skeletal variations occurred at
doses that were not maternally toxic in
the developmental study in rats,
indicating increased quantitative
susceptibility. In rabbits, developmental
effects such as increased liver
porphyrins were observed at doses that
were not maternally toxic, indicating
increased quantitative susceptibility. In
the 2-generation reproduction study in
rats, offspring effects such as increased
number of stillborn pups, decreased
viability and lactation indices,
PO 00000
Frm 00039
Fmt 4700
Sfmt 4700
27257
decreased pre-weaning body weight
and/or body-weight gain, and changes
in hematological parameters were
observed at a dose resulting in less
severe maternal toxicity (decreased food
intake, body weight/weight gain and
changes in hematological parameters
and organ weights indicative of anemia),
indicating increased qualitative
susceptibility.
There was no evidence of
neurotoxicity or neuropathology in the
toxicity database for saflufenacil. In the
acute neurotoxicity study, a decrease in
motor activity was observed on the first
day of dosing at the limit dose in males
only. The finding was not accompanied
by any other neuropathological changes
and was considered a reflection of a
mild and transient general systemic
toxicity and not a substance-specific
neurotoxic effect. In the subchronic
neurotoxicity study, systemic toxicity
(anemia), but no evidence of
neurotoxicity, was seen in males and
females.
There is no evidence of immunotoxity
in the saflufenacil database. The
increase in spleen weight seen only in
rats in the 90-day oral toxicity study is
attributable to an increased clearance of
defective RBCs (i.e., defective
hemoglobin synthesis) and is thus an
indication of toxicity to the
hematopoietic system rather than to the
immune system. In a recently submitted
28-day immunotoxicity study,
saflufenacil failed to induce toxicity
specific to the immune system at the
highest dose tested (i.e., 52 milligrams/
kilogram/bodyweight/day (mg/kg bw/
day)), indicating that saflufenacil does
not directly target the immune system at
the dose levels being used for risk
assessment.
Specific information on the studies
received and the nature of the adverse
effects caused by saflufenacil as well as
the no-observed-adverse-effect-level
(NOAEL) and the lowest-observedadverse-effect-level (LOAEL) from the
toxicity studies can be found at https://
www.regulations.gov in the document
‘‘Saflufenacil. Human-Health Risk
Assessment for Proposed Uses in/on
Vegetable, Legume, Subgroup 6C, pea
and bean (except soybean); Soybean;
Rapeseed Subgroup 20A; Sunflower
Subgroup 20B; and Cottonseed
Subgroup 20C’’ at page 31 in docket ID
number EPA–HQ–OPP–2010–0755.
B. Toxicological Points of Departure/
Levels of Concern
Once a pesticide’s toxicological
profile is determined, EPA identifies
toxicological points of departure (POD)
and levels of concern to use in
evaluating the risk posed by human
E:\FR\FM\11MYR1.SGM
11MYR1
27258
Federal Register / Vol. 76, No. 91 / Wednesday, May 11, 2011 / Rules and Regulations
exposure to the pesticide. For hazards
that have a threshold below which there
is no appreciable risk, the toxicological
POD is used as the basis for derivation
of reference values for risk assessment.
PODs are developed based on a careful
analysis of the doses in each
toxicological study to determine the
dose at which no adverse effects are
observed (the NOAEL) and the lowest
dose at which adverse effects of concern
are identified (the LOAEL). Uncertainty/
safety factors are used in conjunction
with the POD to calculate a safe
exposure level—generally referred to as
a population-adjusted dose (PAD) or a
reference dose (RfD)—and a safe margin
of exposure (MOE). For non-threshold
risks, the Agency assumes that any
amount of exposure will lead to some
degree of risk. Thus, the Agency
estimates risk in terms of the probability
of an occurrence of the adverse effect
expected in a lifetime. For more
information on the general principles
EPA uses in risk characterization and a
complete description of the risk
assessment process, see https://
www.epa.gov/pesticides/factsheets/
riskassess.htm.
A summary of the toxicological
endpoints for saflufenacil used for
human risk assessment is shown in the
following Table.
TABLE—SUMMARY OF TOXICOLOGICAL DOSES AND ENDPOINTS FOR SAFLUFENACIL FOR USE IN HUMAN HEALTH RISK
ASSESSMENT
Point of departure and
uncertainty/safety
factors
Exposure/scenario
Acute dietary (General population including
infants and children).
Chronic dietary (All populations) .....................
Cancer (Oral, dermal, inhalation) ....................
RfD, PAD, LOC for
risk assessment
Study and toxicological effects
NOAEL = 500 mg/kg/
day.
UFA = 10x ..................
UFH = 10x
FQPA SF = 1x
NOAEL= 4.6 mg/kg/
day.
UFA = 10x ..................
UFH = 10x
FQPA SF = 1x
Acute RfD = 5.0 mg/
kg/day.
aPAD = 5.0 mg/kg/day
Acute Neurotoxicity Study in the Rat.
LOAEL = 2,000 mg/kg/day based on decreased motor activity representing mild
and transient systemic toxicity in males. A
LOAEL was not established for females.
Chronic/Carcinogenicity in the Mouse.
LOAEL = 13.8 mg/kg/day based on decreased red blood cells, hemoglobin, and
Ht and porphyria observed in the satellite
group.
Chronic RfD = 0.046
mg/kg/day.
cPAD = 0.046 mg/kg/
day.
Classification: Not likely carcinogenic to humans based on the lack of tumors in the mouse and
rat carcinogenicity studies and lack of mutagenicity.
UFA = extrapolation from animal to human (interspecies). UFH = potential variation in sensitivity among members of the human population
(intraspecies). FQPA SF = Food Quality Protection Act Safety Factor. PAD = population-adjusted dose (a = acute, c = chronic). RfD = reference
dose. LOC = level of concern.
srobinson on DSKHWCL6B1PROD with RULES
C. Exposure Assessment
1. Dietary exposure from food and
feed uses. In evaluating dietary
exposure to saflufenacil, EPA
considered exposure under the
petitioned-for tolerances as well as all
existing saflufenacil tolerances in 40
CFR 180.649. EPA assessed dietary
exposures from saflufenacil in food as
follows:
i. Acute exposure. Quantitative acute
dietary exposure and risk assessments
are performed for a food-use pesticide,
if a toxicological study has indicated the
possibility of an effect of concern
occurring as a result of a 1-day or single
exposure. Such effects were identified
for saflufenacil. In estimating acute
dietary exposure, EPA used food
consumption information from the U.S.
Department of Agriculture (USDA)
1994–1996 and 1998 Nationwide
Continuing Surveys of Food Intake by
Individuals (CSFII). The unrefined
assessment assumed 100% crop treated
(CT), Dietrary Exposure Evaluation
Model (DEEMTM 7.81) default
concentration factors, and tolerancelevel residues for all commodities,
except cottonseed; sunflower subgroup
20B; soybean, seed; vegetable, legume,
subgroup 6C, pea and bean (except
VerDate Mar<15>2010
16:21 May 10, 2011
Jkt 223001
soybean); and rapeseed subgroup 20A,
for which the tolerance levels were
multiplied by a correction factor to
account for a metabolite of concern
which is not included in the tolerance
expression.
ii. Chronic exposure. In conducting
the chronic dietary exposure assessment
EPA used the food consumption data
from the USDA 1994–1996 and 1998
CSFII. Chronic dietary exposure was
assessed using the same food residue
assumptions as in the acute dietary
exposure assessment discussed in Unit
III.C.1.i.
iii. Cancer. Based on the data
summarized in Unit III.A., EPA has
concluded that saflufenacil does not
pose a cancer risk to humans. Therefore,
a dietary exposure assessment for the
purpose of assessing cancer risk is
unnecessary.
iv. Anticipated residue and percent
crop treated (PCT) information. EPA did
not use anticipated residue or PCT
information in the dietary assessment
for saflufenacil. Tolerance level residues
(or, for some commodities, tolerancelevel residues adjusted to account for an
additional metabolite of concern) and
100% CT were assumed for all food
commodities.
PO 00000
Frm 00040
Fmt 4700
Sfmt 4700
2. Dietary exposure from drinking
water. The Agency used screening level
water exposure models in the dietary
exposure analysis and risk assessment
for saflufenacil in drinking water. These
simulation models take into account
data on the physical, chemical, and fate/
transport characteristics of saflufenacil.
Further information regarding EPA
drinking water models used in pesticide
exposure assessment can be found at
https://www.epa.gov/oppefed1/models/
water/index.htm.
Based on the First Index Reservoir
Screening Tool (FIRST) and Pesticide
Root Zone Model/Ground Water
(PRZM/GW), the estimated drinking
water concentrations (EDWCs) of
saflufenacil for acute exposures are
estimated to be 37.3 parts per billion
(ppb) for surface water and 180 ppb for
ground water. EDWCs for chronic
exposures for non-cancer assessments
are estimated to be 23.8 ppb for surface
water and 173 ppb for ground water.
Modeled estimates of drinking water
concentrations were directly entered
into the dietary exposure model. For
acute dietary risk assessment, the water
concentration value of 180 ppb was
used to assess the contribution to
drinking water. For chronic dietary risk
assessment, the water concentration of
E:\FR\FM\11MYR1.SGM
11MYR1
Federal Register / Vol. 76, No. 91 / Wednesday, May 11, 2011 / Rules and Regulations
srobinson on DSKHWCL6B1PROD with RULES
value 173 ppb was used to assess the
contribution to drinking water.
3. From non-dietary exposure. The
term ‘‘residential exposure’’ is used in
this document to refer to nonoccupational, non-dietary exposure
(e.g., for lawn and garden pest control,
indoor pest control, termiticides, and
flea and tick control on pets).
Saflufenacil is not registered for any
specific use patterns that would result
in residential exposure.
4. Cumulative effects from substances
with a common mechanism of toxicity.
Section 408(b)(2)(D)(v) of FFDCA
requires that, when considering whether
to establish, modify, or revoke a
tolerance, the Agency consider
‘‘available information’’ concerning the
cumulative effects of a particular
pesticide’s residues and ‘‘other
substances that have a common
mechanism of toxicity.’’
EPA has not found saflufenacil to
share a common mechanism of toxicity
with any other substances, and
saflufenacil does not appear to produce
a toxic metabolite produced by other
substances. For the purposes of this
tolerance action, therefore, EPA has
assumed that saflufenacil does not have
a common mechanism of toxicity with
other substances. For information
regarding EPA’s efforts to determine
which chemicals have a common
mechanism of toxicity and to evaluate
the cumulative effects of such
chemicals, see EPA’s Web site at
https://www.epa.gov/pesticides/
cumulative.
D. Safety Factor for Infants and
Children
1. In general. Section 408(b)(2)(C) of
FFDCA provides that EPA shall apply
an additional tenfold (10X) margin of
safety for infants and children in the
case of threshold effects to account for
prenatal and postnatal toxicity and the
completeness of the database on toxicity
and exposure unless EPA determines
based on reliable data that a different
margin of safety will be safe for infants
and children. This additional margin of
safety is commonly referred to as the
FQPA Safety Factor (SF). In applying
this provision, EPA either retains the
default value of 10X, or uses a different
additional safety factor when reliable
data available to EPA support the choice
of a different factor.
2. Prenatal and postnatal sensitivity.
The prenatal and postnatal toxicity
database for saflufenacil includes rat
and rabbit developmental toxicity
studies, a two-generation reproduction
toxicity study in rats, acute and
subchronic neurotoxicity studies in rats,
and a 28-day immunotoxicity study in
VerDate Mar<15>2010
16:21 May 10, 2011
Jkt 223001
rats. As discussed in Unit III.A., there
was evidence of quantitative
susceptibility of fetuses to saflufenacil
exposure in the developmental toxicity
studies in rats and rabbits and evidence
of qualitative susceptibility of offspring
in the rat reproduction study.
An analysis was performed to
determine the degree of concern for the
effects observed in the developmental
and reproduction toxicity studies when
considered in the context of all available
toxicity data, and to identify any
residual uncertainties after establishing
toxicity endpoints and traditional UFs
to be used in the risk assessment of
saflufenacil. The degree of concern is
low and there are no residual
uncertainties for the increased
susceptibility since:
i. Clear NOAELs/LOAELs were
established for the developmental
effects seen in rats and rabbits as well
as for the offspring effects seen in the 2generation reproduction study;
ii. Dose-response relationships for the
effects of concern are well
characterized;
iii. None of the effects in the
developmental or reproduction studies
were attributable to a single exposure
and, therefore, are not of concern for
acute risk assessment; and
iv. The dose used to evaluate chronic
dietary risks is lower than the NOAELs
for fetal/offspring effects in the
developmental and reproduction studies
and is, therefore, protective of the
developmental and offspring effects
observed in these studies.
3. Conclusion. EPA has determined
that reliable data show the safety of
infants and children would be
adequately protected if the FQPA SF
were reduced to 1x. That decision is
based on the following findings:
i. The toxicity database for
saflufenacil is complete.
ii. There is no indication that
saflufenacil is a neurotoxic chemical
and there is no need for a
developmental neurotoxicity study or
additional UFs to account for
neurotoxicity.
iii. Although there is evidence of
increased quantitative and qualitative
susceptibility of offspring in the
developmental and reproduction studies
for saflufenacil, the degree of concern is
low and the Agency did not identify any
residual uncertainties after establishing
toxicity endpoints and traditional UFs
to be used in the risk assessment of
saflufenacil.
iv. There are no residual uncertainties
identified in the exposure databases.
The dietary food exposure assessments
were performed based on 100% CT and
tolerance-level residues. EPA made
PO 00000
Frm 00041
Fmt 4700
Sfmt 4700
27259
conservative (protective) assumptions in
the ground- and surface water modeling
used to assess exposure to saflufenacil
in drinking water. These assessments
will not underestimate the exposure and
risks posed by saflufenacil.
E. Aggregate Risks and Determination of
Safety
EPA determines whether acute and
chronic dietary pesticide exposures are
safe by comparing aggregate exposure
estimates to the acute PAD (aPAD) and
chronic PAD (cPAD). For linear cancer
risks, EPA calculates the lifetime
probability of acquiring cancer given the
estimated aggregate exposure. Short-,
intermediate-, and chronic-term risks
are evaluated by comparing the
estimated aggregate food, water, and
residential exposure to the appropriate
PODs to ensure that an adequate MOE
exists.
1. Acute risk. An acute aggregate risk
assessment takes into account acute
exposure estimates from dietary
consumption of food and drinking
water. Using the exposure assumptions
discussed in this unit for acute
exposure, the acute dietary exposure
from food and water to saflufenacil will
occupy less than 1% of the aPAD for all
population subgroups, including infants
and children.
2. Chronic risk. Using the exposure
assumptions described in this unit for
chronic exposure, EPA has concluded
that chronic exposure to saflufenacil
from food and water will utilize 30% of
the cPAD for infants less than 1 year
old, the population group receiving the
greatest exposure. There are no
residential uses for saflufenacil.
3. Short- and intermediate-term risk.
Short- and intermediate-term aggregate
exposure take into account short- or
intermediate-term residential exposure
plus chronic exposure from food and
water (considered to be a background
exposure level). Short- and
intermediate-term adverse effects were
identified; however, saflufenacil is not
registered for any use patterns that
would result in short- or intermediateterm residential exposure. Short- and
intermediate-term risks are assessed
based on short- or intermediate-term
residential exposure plus chronic
dietary exposure. Because there is no
short- or intermediate-term residential
exposure and chronic dietary exposure
has already been assessed under the
appropriately protective cPAD (which is
at least as protective as the POD used to
assess short- and intermediate-term
risk), no further assessment of short- or
intermediate-term risk is necessary, and
EPA relies on the chronic dietary risk
E:\FR\FM\11MYR1.SGM
11MYR1
27260
Federal Register / Vol. 76, No. 91 / Wednesday, May 11, 2011 / Rules and Regulations
assessment for evaluating short- and
intermediate-term risk for saflufenacil.
5. Aggregate cancer risk for U.S.
population. Based on the lack of
evidence of carcinogenicity in two
adequate rodent carcinogenicity studies,
saflufenacil is not expected to pose a
cancer risk to humans.
6. Determination of safety. Based on
these risk assessments, EPA concludes
that there is a reasonable certainty that
no harm will result to the general
population, or to infants and children
from aggregate exposure to saflufenacil
residues.
IV. Other Considerations
A. Analytical Enforcement Methodology
Adequate enforcement methodology
(liquid chromatography/mass
spectroscopy/mass spectroscopy (LC–
MS/MS) methods D0603/02 (plants) and
L0073/01 (livestock)) is available to
enforce the tolerance expression. The
methods may be requested from: Chief,
Analytical Chemistry Branch,
Environmental Science Center, 701
Mapes Rd., Ft. Meade, MD 20755–5350;
telephone number: (410) 305–2905; email address: residuemethods@epa.gov.
B. International Residue Limits
In making its tolerance decisions, EPA
seeks to harmonize U.S. tolerances with
international standards whenever
possible, consistent with U.S. food
safety standards and agricultural
practices. EPA considers the
international maximum residue limits
(MRLs) established by the Codex
Alimentarius Commission (Codex), as
required by FFDCA section 408(b)(4).
The Codex Alimentarius is a joint U.N.
Food and Agriculture Organization/
World Health Organization food
standards program, and it is recognized
as an international food safety
standards-setting organization in trade
agreements to which the United States
is a party. EPA may establish a tolerance
that is different from a Codex MRL;
however, FFDCA section 408(b)(4)
requires that EPA explain the reasons
for departing from the Codex level.
The Codex has not established a MRL
for saflufenacil.
srobinson on DSKHWCL6B1PROD with RULES
C. Revisions to Petitioned-For
Tolerances
EPA has revised the proposed
commodity terms as follows to agree
with the Agency’s Food and Feed
Commodity Vocabulary: ‘‘oilseeds,
cottonseed subgroup 20C, gin
byproducts’’ was changed to ‘‘cotton, gin
byproducts;’’ ‘‘oilseeds, cottonseed
subgroup 20C, undelinted seed’’ was
changed to ‘‘cottonseed subgroup 20C;’’
VerDate Mar<15>2010
16:21 May 10, 2011
Jkt 223001
‘‘oilseeds, sunflower subgroup 20B,
seed’’ was changed to ‘‘sunflower
subgroup 20B;’’ ‘‘soybean, aspirated
grain fractions’’ was changed to ‘‘grain,
aspirated fractions;’’ ‘‘pea, vines’’ was
changed to ‘‘pea, hay;’’ and ‘‘oilseeds,
rapeseed subgroup 20A, seed’’ was
changed to ‘‘rapeseed subgroup 20A.’’
EPA has also revised most of the
proposed tolerance levels. Based on
analysis of the field trial data using the
Agency’s tolerance/MRL calculator in
accordance with the Agency’s
‘‘Guidance for Setting Pesticide
Tolerances Based on Field Trial Data,’’
proposed tolerances were revised for
cotton, gin byproducts from 3.5 ppm to
0.45 ppm; for pea, hay from 8.0 ppm to
17 ppm; and for rapeseed subgroup 20A
from 0.8 ppm to 0.45 ppm. Proposed
tolerances for grain, aspirated fractions
and soybean, seed were increased from
4.52 ppm to 10 ppm and 0.42 ppm to
0.50 ppm, respectively, based on
processing factors (150x for aspirated
grain fractions and 6x for soybean hulls)
derived from a soybean processing
study in conjunction with the highest
average field trial (HAFT) residue of
0.07 ppm from soybean residue studies.
In addition, EPA determined that
separate tolerances were not needed for
dry peas and beans, proposed at 0.1
ppm and 0.5 ppm, respectively. A single
tolerance of 0.30 ppm on ‘‘pea and bean,
dried shelled, except soybean, subgroup
6C’’ was determined to be appropriate
based on analysis of the dry bean field
trial data using the Agency’s tolerance/
MRL calculator. Since residues were
significantly lower in dried peas, they
were not used in calculating the
subgroup 6C tolerance. Finally, based
on calculated livestock dietary burdens
in light of the new tolerances and data
from a cattle feeding study, EPA has
determined that established tolerances
for liver and meat byproducts, except
liver, of cattle, goats, horses, and sheep
should be increased from 0.80 ppm to
2.5 ppm and 0.02 ppm to 0.05 ppm,
respectively.
In conjunction with establishing these
tolerances, the existing tolerance for
‘‘vegetable, foliage of legume, group 7’’ is
being revised to read ‘‘vegetable, foliage
of legume, group 7 (except pea, hay)’’;
the existing tolerance for ‘‘vegetable,
legume, group 6’’ at 0.03 ppm is being
replaced with tolerances on ‘‘vegetable,
legume, edible podded, subgroup 6A’’
and ‘‘pea and bean, succulent shelled,
subgroup 6B’’ at the same level (0.03
ppm); and the existing tolerances for
‘‘sunflower, seed’’ and ‘‘cotton,
undelinted seed,’’ which are superseded
by tolerances on cottonseed subgroup
20C and sunflower subgroup 20B, are
being deleted.
PO 00000
Frm 00042
Fmt 4700
Sfmt 4700
V. Conclusion
Therefore, tolerances are established
or revised for residues of saflufenacil,
including its metabolites and
degradates, in or on the commodities as
codified in the regulatory text in
§ 180.649(a)(1) and (a)(2).
VI. Statutory and Executive Order
Reviews
This final rule establishes tolerances
under section 408(d) of FFDCA in
response to a petition submitted to the
Agency. The Office of Management and
Budget (OMB) has exempted these types
of actions from review under Executive
Order 12866, entitled Regulatory
Planning and Review (58 FR 51735,
October 4, 1993). Because this final rule
has been exempted from review under
Executive Order 12866, this final rule is
not subject to Executive Order 13211,
entitled Actions Concerning Regulations
That Significantly Affect Energy Supply,
Distribution, or Use (66 FR 28355, May
22, 2001) or Executive Order 13045,
entitled Protection of Children from
Environmental Health Risks and Safety
Risks (62 FR 19885, April 23, 1997).
This final rule does not contain any
information collections subject to OMB
approval under the Paperwork
Reduction Act, 44 U.S.C. 3501 et seq.,
nor does it require any special
considerations under Executive Order
12898, entitled Federal Actions To
Address Environmental Justice in
Minority Populations and Low-Income
Populations (59 FR 7629, February 16,
1994).
Since tolerances and exemptions that
are established on the basis of a petition
under section 408(d) of FFDCA, such as
the tolerances in this final rule, do not
require the issuance of a proposed rule,
the requirements of the Regulatory
Flexibility Act (RFA) (5 U.S.C. 601 et
seq.) do not apply.
This final rule directly regulates
growers, food processors, food handlers,
and food retailers, not States or Tribes,
nor does this action alter the
relationships or distribution of power
and responsibilities established by
Congress in the preemption provisions
of section 408(n)(4) of FFDCA. As such,
the Agency has determined that this
action will not have a substantial direct
effect on States or Tribal governments,
on the relationship between the national
government and the States or Tribal
governments, or on the distribution of
power and responsibilities among the
various levels of government or between
the Federal Government and Indian
Tribes. Thus, the Agency has
determined that Executive Order 13132,
entitled Federalism (64 FR 43255,
E:\FR\FM\11MYR1.SGM
11MYR1
Federal Register / Vol. 76, No. 91 / Wednesday, May 11, 2011 / Rules and Regulations
August 10, 1999) and Executive Order
13175, entitled Consultation and
Coordination with Indian Tribal
Governments (65 FR 67249, November
9, 2000) do not apply to this final rule.
In addition, this final rule does not
impose any enforceable duty or contain
any unfunded mandate as described
under Title II of the Unfunded Mandates
Reform Act of 1995 (Pub. L. 104–4).
This action does not involve any
technical standards that would require
Agency consideration of voluntary
consensus standards pursuant to section
12(d) of the National Technology
Transfer and Advancement Act of 1995,
Public Law 104–113, section 12(d) (15
U.S.C. 272 note).
VII. Congressional Review Act
The Congressional Review Act, 5
U.S.C. 801 et seq., generally provides
that before a rule may take effect, the
agency promulgating the rule must
submit a rule report to each House of
the Congress and to the Comptroller
General of the United States. EPA will
submit a report containing this rule and
other required information to the U.S.
Senate, the U.S. House of
Representatives, and the Comptroller
General of the United States prior to
publication of this final rule in the
Federal Register. This final rule is not
a ‘‘major rule’’ as defined by 5 U.S.C.
804(2).
§ 180.649 Saflufenacil; tolerances for
residues.
*
(a) * * * (1) * * *
Parts per
million
Commodity
Almond, hulls ............................
Cotton, gin byproducts .............
Cottonseed subgroup 20C .......
Fruit, citrus, group 10 ...............
Fruit, pome, group 11 ...............
Fruit, stone, group 12 ...............
Grain, aspirated fractions .........
Grain, cereal, forage, fodder
and straw group 16 ...............
Grain, cereal, group 15 ............
Grape ........................................
Nut, tree, group 14 ...................
Pea and bean, dried shelled,
except soybean, subgroup
6C ..........................................
Pea and bean, succulent
shelled, subgroup 6B ............
Pea, hay ...................................
Pistachio ...................................
Rapeseed subgroup 20A ..........
Sunflower subgroup 20B ..........
Soybean, hulls ..........................
Soybean, seed ..........................
Vegetable, foliage of legume,
group 7 (except pea, hay) ....
Vegetable, legume, edible podded, subgroup 6A .................
0.10
0.45
0.20
0.03
0.03
0.03
10
0.10
0.03
0.03
0.03
0.30
0.03
17
0.03
0.45
1.0
0.50
0.10
0.10
0.03
(2) * * *
Parts per
million
Commodity
*
2.5
Dated: May 3, 2011.
Lois Rossi,
Director, Registration Division, Office of
Pesticide Programs.
*
*
*
*
Cattle, meat byproducts, except
liver ........................................
*
0.05
Therefore, 40 CFR chapter I is
amended as follows:
*
*
*
*
Goat, liver .................................
*
2.5
PART 180—[AMENDED]
*
*
*
*
Goat, meat byproducts, except
liver ........................................
*
0.05
*
*
*
*
Horse, liver ...............................
*
2.5
*
*
*
*
Horse, meat byproducts, except
liver ........................................
*
0.05
*
*
*
*
Sheep, liver ...............................
*
2.5
*
*
*
*
Sheep, meat byproducts, except liver ................................
*
1. The authority citation for part 180
continues to read as follows:
Authority: 21 U.S.C. 321(q), 346a and 371.
2. Section 180.649 is amended as
follows:
■ a. Revise the table in paragraph (a)(1).
■ b. In the table in paragraph (a)(2),
revise the entries for cattle, liver; cattle,
meat byproducts, except liver; goat,
liver; goat, meat byproducts, except
liver; horse, liver; horse, meat
byproducts, except liver; sheep, liver;
and sheep, meat byproducts, except
liver.
The revised texts read as follows:
srobinson on DSKHWCL6B1PROD with RULES
■
VerDate Mar<15>2010
16:21 May 10, 2011
Jkt 223001
PO 00000
*
*
Frm 00043
*
Fmt 4700
*
*
BILLING CODE 6560–50–P
*
*
*
*
Cattle, liver ................................
■
*
[FR Doc. 2011–11553 Filed 5–10–11; 8:45 am]
List of Subjects in 40 CFR Part 180
Environmental protection,
Administrative practice and procedure,
Agricultural commodities, Pesticides
and pests, Reporting and recordkeeping
requirements.
*
27261
*
Sfmt 4700
0.05
*
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2009–1009; FRL–8873–2]
Propiconazole; Pesticide Tolerances
Environmental Protection
Agency (EPA).
ACTION: Final rule.
AGENCY:
This regulation establishes
tolerances for residues of propiconazole
in or on multiple commodities which
are identified and discussed later in this
document. Interregional Research
Project #4 (IR–4) requested these
tolerances under the Federal Food,
Drug, and Cosmetic Act (FFDCA). In
addition, this action establishes a timelimited tolerance for residues of
propiconazole in or on avocado, in
response to the approval of a quarantine
exemption under the Federal
Insecticide, Fungicide, and Rodenticide
Act (FIFRA) authorizing use to control
the disease, laurel wilt (caused by
Raffaelea lauricola) in the state of
Florida. This regulation establishes a
maximum permissible level of residues
of propiconazole in this food
commodity. The time-limited tolerance
expires and is revoked on December 31,
2013.
DATES: This regulation is effective May
11, 2011. Objections and requests for
hearings must be received on or before
July 11, 2011, and must be filed in
accordance with the instructions
provided in 40 CFR part 178 (see also
Unit I.C. of the SUPPLEMENTARY
INFORMATION).
ADDRESSES: EPA has established a
docket for this action under docket
identification (ID) number EPA–HQ–
OPP–2009–1009. All documents in the
docket are listed in the docket index
available at https://www.regulations.gov.
Although listed in the index, some
information is not publicly available,
e.g., Confidential Business Information
(CBI) or other information whose
disclosure is restricted by statute.
Certain other material, such as
copyrighted material, is not placed on
the Internet and will be publicly
available only in hard copy form.
Publicly available docket materials are
available in the electronic docket at
https://www.regulations.gov, or, if only
available in hard copy, at the OPP
Regulatory Public Docket in Rm. S–
4400, One Potomac Yard (South Bldg.),
SUMMARY:
E:\FR\FM\11MYR1.SGM
11MYR1
Agencies
[Federal Register Volume 76, Number 91 (Wednesday, May 11, 2011)]
[Rules and Regulations]
[Pages 27256-27261]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-11553]
[[Page 27256]]
=======================================================================
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 180
[EPA-HQ-OPP-2010-0755; FRL-8872-7]
Saflufenacil; Pesticide Tolerances
AGENCY: Environmental Protection Agency (EPA).
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This regulation revises or removes certain established
tolerances and establishes new tolerances for residues of saflufenacil
in or on multiple commodities which are identified and discussed later
in this document. BASF Corporation requested these tolerances under the
Federal Food, Drug, and Cosmetic Act (FFDCA).
DATES: This regulation is effective May 11, 2011. Objections and
requests for hearings must be received on or before July 11, 2011, and
must be filed in accordance with the instructions provided in 40 CFR
part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).
ADDRESSES: EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2010-0755. All documents in the
docket are listed in the docket index available at https://www.regulations.gov. Although listed in the index, some information is
not publicly available, e.g., Confidential Business Information (CBI)
or other information whose disclosure is restricted by statute. Certain
other material, such as copyrighted material, is not placed on the
Internet and will be publicly available only in hard copy form.
Publicly available docket materials are available in the electronic
docket at https://www.regulations.gov, or, if only available in hard
copy, at the OPP Regulatory Public Docket in Rm. S-4400, One Potomac
Yard (South Bldg.), 2777 S. Crystal Dr., Arlington, VA. The Docket
Facility is open from 8:30 a.m. to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket Facility telephone number is (703)
305-5805.
FOR FURTHER INFORMATION CONTACT: Susan Stanton, Registration Division
(7505P), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone
number: (703) 305-5218; e-mail address: stanton.susan@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
Potentially affected entities may include, but are not limited to those
engaged in the following activities:
Crop production (NAICS code 111).
Animal production (NAICS code 112).
Food manufacturing (NAICS code 311).
Pesticide manufacturing (NAICS code 32532).
This listing is not intended to be exhaustive, but rather to
provide a guide for readers regarding entities likely to be affected by
this action. Other types of entities not listed in this unit could also
be affected. The North American Industrial Classification System
(NAICS) codes have been provided to assist you and others in
determining whether this action might apply to certain entities. If you
have any questions regarding the applicability of this action to a
particular entity, consult the person listed under FOR FURTHER
INFORMATION CONTACT.
B. How can I get electronic access to other related information?
You may access a frequently updated electronic version of EPA's
tolerance regulations at 40 CFR part 180 through the Government
Printing Office's e-CFR site at https://www.gpoaccess.gov/ecfr.
C. How can I file an objection or hearing request?
Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an
objection to any aspect of this regulation and may also request a
hearing on those objections. You must file your objection or request a
hearing on this regulation in accordance with the instructions provided
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify
docket ID number EPA-HQ-OPP-2010-0755 in the subject line on the first
page of your submission. All objections and requests for a hearing must
be in writing, and must be received by the Hearing Clerk on or before
July 11, 2011. Addresses for mail and hand delivery of objections and
hearing requests are provided in 40 CFR 178.25(b).
In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing that does not contain any CBI for inclusion in the public
docket. Information not marked confidential pursuant to 40 CFR part 2
may be disclosed publicly by EPA without prior notice. Submit a copy of
your non-CBI objection or hearing request, identified by docket ID
number EPA-HQ-OPP-2010-0755, by one of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the on-line instructions for submitting comments.
Mail: Office of Pesticide Programs (OPP) Regulatory Public
Docket (7502P), Environmental Protection Agency, 1200 Pennsylvania
Ave., NW., Washington, DC 20460-0001.
Delivery: OPP Regulatory Public Docket (7502P),
Environmental Protection Agency, Rm. S-4400, One Potomac Yard (South
Bldg.), 2777 S. Crystal Dr., Arlington, VA. Deliveries are only
accepted during the Docket Facility's normal hours of operation (8:30
a.m. to 4 p.m., Monday through Friday, excluding legal holidays).
Special arrangements should be made for deliveries of boxed
information. The Docket Facility telephone number is (703) 305-5805.
II. Summary of Petitioned-For Tolerance
In the Federal Register of September 23, 2010 (75 FR 57942) (FRL-
8845-4), EPA issued a notice pursuant to section 408(d)(3) of FFDCA, 21
U.S.C. 346a(d)(3), announcing the filing of pesticide petitions (PP
0F7744 and PP 0F7766) by BASF Corporation, 26 Davis Drive, P.O. Box
13528, Research Triangle Park, NC 27709-3528. The petitions requested
that 40 CFR 180.649 be amended by establishing tolerances for residues
of the herbicide saflufenacil, 2-chloro-5-[3,6-dihydro-3-methyl-2,6-
dioxo-4-(trifluoromethyl)-1(2 H)-pyrimidinyl]-4-fluoro- N-[[methyl(1-
methylethyl)amino]sulfonyl]benzamide, and its metabolites N-[2-chloro-
5-(2,6-dioxo-4-(trifluoromethyl)-3,6-dihydro-1(2 H)-pyrimidinyl)-4-
fluorobenzoyl]- N-'isopropylsulfamide and N-[4-chloro-2-fluoro-5-
({[(isopropylamino)sulfonyl]amino{time} carbonyl)phenyl]urea,
calculated as the stoichiometric equivalent of saflufenacil, in or on
oilseeds, cottonseed subgroup 20C, gin byproducts at 3.5 parts per
million (ppm); oilseeds, cottonseed subgroup 20C, undelinted seed at
0.2 ppm; oilseeds, sunflower subgroup 20B, seed at 1.0 ppm; pea, vines
at 8.0 ppm; soybean, aspirated grain fractions at 4.52 ppm; soybean,
hulls at 0.42 ppm; soybean, seed at 0.1 ppm; vegetable, legume,
subgroup 6C, beans, dry at 0.5 ppm; and vegetable, legume, subgroup 6C,
peas, dry at 0.1 ppm (PP 0F7744); and in or on oilseeds, rapeseed
subgroup 20A, seed at 0.8 ppm (PP 0F7766). That notice referenced
[[Page 27257]]
summaries of the petitions prepared by BASF Corporation, the
registrant, which are available in the docket, https://www.regulations.gov. There were no comments received in response to the
notice of filing.
Based upon review of the data supporting the petition, EPA has
revised the proposed commodity terms and tolerance levels for several
commodities and determined that established tolerances for certain
livestock commodities should be increased. The reasons for these
changes are explained in Unit IV.C.
III. Aggregate Risk Assessment and Determination of Safety
Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This includes exposure through drinking water and in
residential settings, but does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical residue.''
Consistent with section 408(b)(2)(D) of FFDCA, and the factors
specified in section 408(b)(2)(D) of FFDCA, EPA has reviewed the
available scientific data and other relevant information in support of
this action. EPA has sufficient data to assess the hazards of and to
make a determination on aggregate exposure for saflufenacil including
exposure resulting from the tolerances established by this action.
EPA's assessment of exposures and risks associated with saflufenacil
follows.
A. Toxicological Profile
EPA has evaluated the available toxicity data and considered its
validity, completeness, and reliability as well as the relationship of
the results of the studies to human risk. EPA has also considered
available information concerning the variability of the sensitivities
of major identifiable subgroups of consumers, including infants and
children.
Saflufenacil has low acute toxicity via the oral, dermal, and
inhalation routes of exposure. It is slightly irritating to the eye but
is neither a dermal irritant nor sensitizer.
Short-term, subchronic, and chronic toxicity studies in rats, mice,
and dogs identified the hematopoietic system as the target organ of
saflufenacil. Protoporphyrinogen oxidase inhibition in the mammalian
species may result in disruption of heme synthesis which in turn causes
anemia. In these studies, decreased hematological parameters [red blood
cells (RBC), hematocrit (Ht), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin
concentration (MCHC)] were seen at about the same dose level across
species, except in the case of the dog, where the effects were seen at
a slightly higher dose. These effects occurred around the same dose
level from the short- through long-term exposures without increasing in
severity. Effects were also seen in the liver (increased weight,
centrilobular fatty change, and lymphoid infiltrate) in mice, the
spleen (increased spleen weight and extramedullary hematopoiesis) in
rats, and in both these organs (increased iron storage in the liver and
extramedullary hematopoiesis in the spleen) in dogs. No dermal toxicity
was seen at the limit dose in a 28-day dermal toxicity study in rats.
Carcinogenicity studies in rats and mice showed no evidence of
increased incidence of tumors at the tested doses. Saflufenacil is
weakly clastogenic in the in vitro chromosomal aberration assay in V79
cells in the presence of S9 activation; however, the response was not
evident in the absence of S9 activation. It is neither mutagenic in
bacterial cells nor clastogenic in rodents in vivo. Saflufenacil is
classified as ``not likely to be carcinogenic to humans.''
Increased fetal and offspring susceptibility to saflufenacil were
observed in the developmental toxicity studies in the rat and rabbit
and in the 2-generation reproduction study in the rat. Developmental
effects such as decreased fetal body weights and increased skeletal
variations occurred at doses that were not maternally toxic in the
developmental study in rats, indicating increased quantitative
susceptibility. In rabbits, developmental effects such as increased
liver porphyrins were observed at doses that were not maternally toxic,
indicating increased quantitative susceptibility. In the 2-generation
reproduction study in rats, offspring effects such as increased number
of stillborn pups, decreased viability and lactation indices, decreased
pre-weaning body weight and/or body-weight gain, and changes in
hematological parameters were observed at a dose resulting in less
severe maternal toxicity (decreased food intake, body weight/weight
gain and changes in hematological parameters and organ weights
indicative of anemia), indicating increased qualitative susceptibility.
There was no evidence of neurotoxicity or neuropathology in the
toxicity database for saflufenacil. In the acute neurotoxicity study, a
decrease in motor activity was observed on the first day of dosing at
the limit dose in males only. The finding was not accompanied by any
other neuropathological changes and was considered a reflection of a
mild and transient general systemic toxicity and not a substance-
specific neurotoxic effect. In the subchronic neurotoxicity study,
systemic toxicity (anemia), but no evidence of neurotoxicity, was seen
in males and females.
There is no evidence of immunotoxity in the saflufenacil database.
The increase in spleen weight seen only in rats in the 90-day oral
toxicity study is attributable to an increased clearance of defective
RBCs (i.e., defective hemoglobin synthesis) and is thus an indication
of toxicity to the hematopoietic system rather than to the immune
system. In a recently submitted 28-day immunotoxicity study,
saflufenacil failed to induce toxicity specific to the immune system at
the highest dose tested (i.e., 52 milligrams/kilogram/bodyweight/day
(mg/kg bw/day)), indicating that saflufenacil does not directly target
the immune system at the dose levels being used for risk assessment.
Specific information on the studies received and the nature of the
adverse effects caused by saflufenacil as well as the no-observed-
adverse-effect-level (NOAEL) and the lowest-observed-adverse-effect-
level (LOAEL) from the toxicity studies can be found at https://www.regulations.gov in the document ``Saflufenacil. Human-Health Risk
Assessment for Proposed Uses in/on Vegetable, Legume, Subgroup 6C, pea
and bean (except soybean); Soybean; Rapeseed Subgroup 20A; Sunflower
Subgroup 20B; and Cottonseed Subgroup 20C'' at page 31 in docket ID
number EPA-HQ-OPP-2010-0755.
B. Toxicological Points of Departure/Levels of Concern
Once a pesticide's toxicological profile is determined, EPA
identifies toxicological points of departure (POD) and levels of
concern to use in evaluating the risk posed by human
[[Page 27258]]
exposure to the pesticide. For hazards that have a threshold below
which there is no appreciable risk, the toxicological POD is used as
the basis for derivation of reference values for risk assessment. PODs
are developed based on a careful analysis of the doses in each
toxicological study to determine the dose at which no adverse effects
are observed (the NOAEL) and the lowest dose at which adverse effects
of concern are identified (the LOAEL). Uncertainty/safety factors are
used in conjunction with the POD to calculate a safe exposure level--
generally referred to as a population-adjusted dose (PAD) or a
reference dose (RfD)--and a safe margin of exposure (MOE). For non-
threshold risks, the Agency assumes that any amount of exposure will
lead to some degree of risk. Thus, the Agency estimates risk in terms
of the probability of an occurrence of the adverse effect expected in a
lifetime. For more information on the general principles EPA uses in
risk characterization and a complete description of the risk assessment
process, see https://www.epa.gov/pesticides/factsheets/riskassess.htm.
A summary of the toxicological endpoints for saflufenacil used for
human risk assessment is shown in the following Table.
Table--Summary of Toxicological Doses and Endpoints for Saflufenacil for Use in Human Health Risk Assessment
----------------------------------------------------------------------------------------------------------------
Point of departure and
Exposure/scenario uncertainty/safety RfD, PAD, LOC for risk Study and toxicological
factors assessment effects
----------------------------------------------------------------------------------------------------------------
Acute dietary (General population NOAEL = 500 mg/kg/day.. Acute RfD = 5.0 mg/kg/ Acute Neurotoxicity
including infants and children). UFA = 10x.............. day. Study in the Rat.
UFH = 10x.............. aPAD = 5.0 mg/kg/day... LOAEL = 2,000 mg/kg/day
FQPA SF = 1x........... based on decreased
motor activity
representing mild and
transient systemic
toxicity in males. A
LOAEL was not
established for
females.
Chronic dietary (All populations)... NOAEL= 4.6 mg/kg/day... Chronic RfD = 0.046 mg/ Chronic/Carcinogenicity
UFA = 10x.............. kg/day. in the Mouse.
UFH = 10x.............. cPAD = 0.046 mg/kg/day. LOAEL = 13.8 mg/kg/day
FQPA SF = 1x........... based on decreased red
blood cells,
hemoglobin, and Ht and
porphyria observed in
the satellite group.
---------------------------------------------------------------------------
Cancer (Oral, dermal, inhalation)... Classification: Not likely carcinogenic to humans based on the lack of
tumors in the mouse and rat carcinogenicity studies and lack of
mutagenicity.
----------------------------------------------------------------------------------------------------------------
UFA = extrapolation from animal to human (interspecies). UFH = potential variation in sensitivity among members
of the human population (intraspecies). FQPA SF = Food Quality Protection Act Safety Factor. PAD = population-
adjusted dose (a = acute, c = chronic). RfD = reference dose. LOC = level of concern.
C. Exposure Assessment
1. Dietary exposure from food and feed uses. In evaluating dietary
exposure to saflufenacil, EPA considered exposure under the petitioned-
for tolerances as well as all existing saflufenacil tolerances in 40
CFR 180.649. EPA assessed dietary exposures from saflufenacil in food
as follows:
i. Acute exposure. Quantitative acute dietary exposure and risk
assessments are performed for a food-use pesticide, if a toxicological
study has indicated the possibility of an effect of concern occurring
as a result of a 1-day or single exposure. Such effects were identified
for saflufenacil. In estimating acute dietary exposure, EPA used food
consumption information from the U.S. Department of Agriculture (USDA)
1994-1996 and 1998 Nationwide Continuing Surveys of Food Intake by
Individuals (CSFII). The unrefined assessment assumed 100% crop treated
(CT), Dietrary Exposure Evaluation Model (DEEMTM 7.81)
default concentration factors, and tolerance-level residues for all
commodities, except cottonseed; sunflower subgroup 20B; soybean, seed;
vegetable, legume, subgroup 6C, pea and bean (except soybean); and
rapeseed subgroup 20A, for which the tolerance levels were multiplied
by a correction factor to account for a metabolite of concern which is
not included in the tolerance expression.
ii. Chronic exposure. In conducting the chronic dietary exposure
assessment EPA used the food consumption data from the USDA 1994-1996
and 1998 CSFII. Chronic dietary exposure was assessed using the same
food residue assumptions as in the acute dietary exposure assessment
discussed in Unit III.C.1.i.
iii. Cancer. Based on the data summarized in Unit III.A., EPA has
concluded that saflufenacil does not pose a cancer risk to humans.
Therefore, a dietary exposure assessment for the purpose of assessing
cancer risk is unnecessary.
iv. Anticipated residue and percent crop treated (PCT) information.
EPA did not use anticipated residue or PCT information in the dietary
assessment for saflufenacil. Tolerance level residues (or, for some
commodities, tolerance-level residues adjusted to account for an
additional metabolite of concern) and 100% CT were assumed for all food
commodities.
2. Dietary exposure from drinking water. The Agency used screening
level water exposure models in the dietary exposure analysis and risk
assessment for saflufenacil in drinking water. These simulation models
take into account data on the physical, chemical, and fate/transport
characteristics of saflufenacil. Further information regarding EPA
drinking water models used in pesticide exposure assessment can be
found at https://www.epa.gov/oppefed1/models/water/index.htm.
Based on the First Index Reservoir Screening Tool (FIRST) and
Pesticide Root Zone Model/Ground Water (PRZM/GW), the estimated
drinking water concentrations (EDWCs) of saflufenacil for acute
exposures are estimated to be 37.3 parts per billion (ppb) for surface
water and 180 ppb for ground water. EDWCs for chronic exposures for
non-cancer assessments are estimated to be 23.8 ppb for surface water
and 173 ppb for ground water.
Modeled estimates of drinking water concentrations were directly
entered into the dietary exposure model. For acute dietary risk
assessment, the water concentration value of 180 ppb was used to assess
the contribution to drinking water. For chronic dietary risk
assessment, the water concentration of
[[Page 27259]]
value 173 ppb was used to assess the contribution to drinking water.
3. From non-dietary exposure. The term ``residential exposure'' is
used in this document to refer to non-occupational, non-dietary
exposure (e.g., for lawn and garden pest control, indoor pest control,
termiticides, and flea and tick control on pets). Saflufenacil is not
registered for any specific use patterns that would result in
residential exposure.
4. Cumulative effects from substances with a common mechanism of
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when
considering whether to establish, modify, or revoke a tolerance, the
Agency consider ``available information'' concerning the cumulative
effects of a particular pesticide's residues and ``other substances
that have a common mechanism of toxicity.''
EPA has not found saflufenacil to share a common mechanism of
toxicity with any other substances, and saflufenacil does not appear to
produce a toxic metabolite produced by other substances. For the
purposes of this tolerance action, therefore, EPA has assumed that
saflufenacil does not have a common mechanism of toxicity with other
substances. For information regarding EPA's efforts to determine which
chemicals have a common mechanism of toxicity and to evaluate the
cumulative effects of such chemicals, see EPA's Web site at https://www.epa.gov/pesticides/cumulative.
D. Safety Factor for Infants and Children
1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA
shall apply an additional tenfold (10X) margin of safety for infants
and children in the case of threshold effects to account for prenatal
and postnatal toxicity and the completeness of the database on toxicity
and exposure unless EPA determines based on reliable data that a
different margin of safety will be safe for infants and children. This
additional margin of safety is commonly referred to as the FQPA Safety
Factor (SF). In applying this provision, EPA either retains the default
value of 10X, or uses a different additional safety factor when
reliable data available to EPA support the choice of a different
factor.
2. Prenatal and postnatal sensitivity. The prenatal and postnatal
toxicity database for saflufenacil includes rat and rabbit
developmental toxicity studies, a two-generation reproduction toxicity
study in rats, acute and subchronic neurotoxicity studies in rats, and
a 28-day immunotoxicity study in rats. As discussed in Unit III.A.,
there was evidence of quantitative susceptibility of fetuses to
saflufenacil exposure in the developmental toxicity studies in rats and
rabbits and evidence of qualitative susceptibility of offspring in the
rat reproduction study.
An analysis was performed to determine the degree of concern for
the effects observed in the developmental and reproduction toxicity
studies when considered in the context of all available toxicity data,
and to identify any residual uncertainties after establishing toxicity
endpoints and traditional UFs to be used in the risk assessment of
saflufenacil. The degree of concern is low and there are no residual
uncertainties for the increased susceptibility since:
i. Clear NOAELs/LOAELs were established for the developmental
effects seen in rats and rabbits as well as for the offspring effects
seen in the 2-generation reproduction study;
ii. Dose-response relationships for the effects of concern are well
characterized;
iii. None of the effects in the developmental or reproduction
studies were attributable to a single exposure and, therefore, are not
of concern for acute risk assessment; and
iv. The dose used to evaluate chronic dietary risks is lower than
the NOAELs for fetal/offspring effects in the developmental and
reproduction studies and is, therefore, protective of the developmental
and offspring effects observed in these studies.
3. Conclusion. EPA has determined that reliable data show the
safety of infants and children would be adequately protected if the
FQPA SF were reduced to 1x. That decision is based on the following
findings:
i. The toxicity database for saflufenacil is complete.
ii. There is no indication that saflufenacil is a neurotoxic
chemical and there is no need for a developmental neurotoxicity study
or additional UFs to account for neurotoxicity.
iii. Although there is evidence of increased quantitative and
qualitative susceptibility of offspring in the developmental and
reproduction studies for saflufenacil, the degree of concern is low and
the Agency did not identify any residual uncertainties after
establishing toxicity endpoints and traditional UFs to be used in the
risk assessment of saflufenacil.
iv. There are no residual uncertainties identified in the exposure
databases. The dietary food exposure assessments were performed based
on 100% CT and tolerance-level residues. EPA made conservative
(protective) assumptions in the ground- and surface water modeling used
to assess exposure to saflufenacil in drinking water. These assessments
will not underestimate the exposure and risks posed by saflufenacil.
E. Aggregate Risks and Determination of Safety
EPA determines whether acute and chronic dietary pesticide
exposures are safe by comparing aggregate exposure estimates to the
acute PAD (aPAD) and chronic PAD (cPAD). For linear cancer risks, EPA
calculates the lifetime probability of acquiring cancer given the
estimated aggregate exposure. Short-, intermediate-, and chronic-term
risks are evaluated by comparing the estimated aggregate food, water,
and residential exposure to the appropriate PODs to ensure that an
adequate MOE exists.
1. Acute risk. An acute aggregate risk assessment takes into
account acute exposure estimates from dietary consumption of food and
drinking water. Using the exposure assumptions discussed in this unit
for acute exposure, the acute dietary exposure from food and water to
saflufenacil will occupy less than 1% of the aPAD for all population
subgroups, including infants and children.
2. Chronic risk. Using the exposure assumptions described in this
unit for chronic exposure, EPA has concluded that chronic exposure to
saflufenacil from food and water will utilize 30% of the cPAD for
infants less than 1 year old, the population group receiving the
greatest exposure. There are no residential uses for saflufenacil.
3. Short- and intermediate-term risk. Short- and intermediate-term
aggregate exposure take into account short- or intermediate-term
residential exposure plus chronic exposure from food and water
(considered to be a background exposure level). Short- and
intermediate-term adverse effects were identified; however,
saflufenacil is not registered for any use patterns that would result
in short- or intermediate-term residential exposure. Short- and
intermediate-term risks are assessed based on short- or intermediate-
term residential exposure plus chronic dietary exposure. Because there
is no short- or intermediate-term residential exposure and chronic
dietary exposure has already been assessed under the appropriately
protective cPAD (which is at least as protective as the POD used to
assess short- and intermediate-term risk), no further assessment of
short- or intermediate-term risk is necessary, and EPA relies on the
chronic dietary risk
[[Page 27260]]
assessment for evaluating short- and intermediate-term risk for
saflufenacil.
5. Aggregate cancer risk for U.S. population. Based on the lack of
evidence of carcinogenicity in two adequate rodent carcinogenicity
studies, saflufenacil is not expected to pose a cancer risk to humans.
6. Determination of safety. Based on these risk assessments, EPA
concludes that there is a reasonable certainty that no harm will result
to the general population, or to infants and children from aggregate
exposure to saflufenacil residues.
IV. Other Considerations
A. Analytical Enforcement Methodology
Adequate enforcement methodology (liquid chromatography/mass
spectroscopy/mass spectroscopy (LC-MS/MS) methods D0603/02 (plants) and
L0073/01 (livestock)) is available to enforce the tolerance expression.
The methods may be requested from: Chief, Analytical Chemistry Branch,
Environmental Science Center, 701 Mapes Rd., Ft. Meade, MD 20755-5350;
telephone number: (410) 305-2905; e-mail address:
residuemethods@epa.gov.
B. International Residue Limits
In making its tolerance decisions, EPA seeks to harmonize U.S.
tolerances with international standards whenever possible, consistent
with U.S. food safety standards and agricultural practices. EPA
considers the international maximum residue limits (MRLs) established
by the Codex Alimentarius Commission (Codex), as required by FFDCA
section 408(b)(4). The Codex Alimentarius is a joint U.N. Food and
Agriculture Organization/World Health Organization food standards
program, and it is recognized as an international food safety
standards-setting organization in trade agreements to which the United
States is a party. EPA may establish a tolerance that is different from
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain
the reasons for departing from the Codex level.
The Codex has not established a MRL for saflufenacil.
C. Revisions to Petitioned-For Tolerances
EPA has revised the proposed commodity terms as follows to agree
with the Agency's Food and Feed Commodity Vocabulary: ``oilseeds,
cottonseed subgroup 20C, gin byproducts'' was changed to ``cotton, gin
byproducts;'' ``oilseeds, cottonseed subgroup 20C, undelinted seed''
was changed to ``cottonseed subgroup 20C;'' ``oilseeds, sunflower
subgroup 20B, seed'' was changed to ``sunflower subgroup 20B;''
``soybean, aspirated grain fractions'' was changed to ``grain,
aspirated fractions;'' ``pea, vines'' was changed to ``pea, hay;'' and
``oilseeds, rapeseed subgroup 20A, seed'' was changed to ``rapeseed
subgroup 20A.''
EPA has also revised most of the proposed tolerance levels. Based
on analysis of the field trial data using the Agency's tolerance/MRL
calculator in accordance with the Agency's ``Guidance for Setting
Pesticide Tolerances Based on Field Trial Data,'' proposed tolerances
were revised for cotton, gin byproducts from 3.5 ppm to 0.45 ppm; for
pea, hay from 8.0 ppm to 17 ppm; and for rapeseed subgroup 20A from 0.8
ppm to 0.45 ppm. Proposed tolerances for grain, aspirated fractions and
soybean, seed were increased from 4.52 ppm to 10 ppm and 0.42 ppm to
0.50 ppm, respectively, based on processing factors (150x for aspirated
grain fractions and 6x for soybean hulls) derived from a soybean
processing study in conjunction with the highest average field trial
(HAFT) residue of 0.07 ppm from soybean residue studies. In addition,
EPA determined that separate tolerances were not needed for dry peas
and beans, proposed at 0.1 ppm and 0.5 ppm, respectively. A single
tolerance of 0.30 ppm on ``pea and bean, dried shelled, except soybean,
subgroup 6C'' was determined to be appropriate based on analysis of the
dry bean field trial data using the Agency's tolerance/MRL calculator.
Since residues were significantly lower in dried peas, they were not
used in calculating the subgroup 6C tolerance. Finally, based on
calculated livestock dietary burdens in light of the new tolerances and
data from a cattle feeding study, EPA has determined that established
tolerances for liver and meat byproducts, except liver, of cattle,
goats, horses, and sheep should be increased from 0.80 ppm to 2.5 ppm
and 0.02 ppm to 0.05 ppm, respectively.
In conjunction with establishing these tolerances, the existing
tolerance for ``vegetable, foliage of legume, group 7'' is being
revised to read ``vegetable, foliage of legume, group 7 (except pea,
hay)''; the existing tolerance for ``vegetable, legume, group 6'' at
0.03 ppm is being replaced with tolerances on ``vegetable, legume,
edible podded, subgroup 6A'' and ``pea and bean, succulent shelled,
subgroup 6B'' at the same level (0.03 ppm); and the existing tolerances
for ``sunflower, seed'' and ``cotton, undelinted seed,'' which are
superseded by tolerances on cottonseed subgroup 20C and sunflower
subgroup 20B, are being deleted.
V. Conclusion
Therefore, tolerances are established or revised for residues of
saflufenacil, including its metabolites and degradates, in or on the
commodities as codified in the regulatory text in Sec. 180.649(a)(1)
and (a)(2).
VI. Statutory and Executive Order Reviews
This final rule establishes tolerances under section 408(d) of
FFDCA in response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled Regulatory Planning and
Review (58 FR 51735, October 4, 1993). Because this final rule has been
exempted from review under Executive Order 12866, this final rule is
not subject to Executive Order 13211, entitled Actions Concerning
Regulations That Significantly Affect Energy Supply, Distribution, or
Use (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled
Protection of Children from Environmental Health Risks and Safety Risks
(62 FR 19885, April 23, 1997). This final rule does not contain any
information collections subject to OMB approval under the Paperwork
Reduction Act, 44 U.S.C. 3501 et seq., nor does it require any special
considerations under Executive Order 12898, entitled Federal Actions To
Address Environmental Justice in Minority Populations and Low-Income
Populations (59 FR 7629, February 16, 1994).
Since tolerances and exemptions that are established on the basis
of a petition under section 408(d) of FFDCA, such as the tolerances in
this final rule, do not require the issuance of a proposed rule, the
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq.) do not apply.
This final rule directly regulates growers, food processors, food
handlers, and food retailers, not States or Tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of section 408(n)(4) of FFDCA. As such, the Agency has determined that
this action will not have a substantial direct effect on States or
Tribal governments, on the relationship between the national government
and the States or Tribal governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian Tribes. Thus, the Agency has
determined that Executive Order 13132, entitled Federalism (64 FR
43255,
[[Page 27261]]
August 10, 1999) and Executive Order 13175, entitled Consultation and
Coordination with Indian Tribal Governments (65 FR 67249, November 9,
2000) do not apply to this final rule. In addition, this final rule
does not impose any enforceable duty or contain any unfunded mandate as
described under Title II of the Unfunded Mandates Reform Act of 1995
(Pub. L. 104-4).
This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act of 1995, Public Law 104-113, section 12(d) (15 U.S.C. 272 note).
VII. Congressional Review Act
The Congressional Review Act, 5 U.S.C. 801 et seq., generally
provides that before a rule may take effect, the agency promulgating
the rule must submit a rule report to each House of the Congress and to
the Comptroller General of the United States. EPA will submit a report
containing this rule and other required information to the U.S. Senate,
the U.S. House of Representatives, and the Comptroller General of the
United States prior to publication of this final rule in the Federal
Register. This final rule is not a ``major rule'' as defined by 5
U.S.C. 804(2).
List of Subjects in 40 CFR Part 180
Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.
Dated: May 3, 2011.
Lois Rossi,
Director, Registration Division, Office of Pesticide Programs.
Therefore, 40 CFR chapter I is amended as follows:
PART 180--[AMENDED]
0
1. The authority citation for part 180 continues to read as follows:
Authority: 21 U.S.C. 321(q), 346a and 371.
0
2. Section 180.649 is amended as follows:
0
a. Revise the table in paragraph (a)(1).
0
b. In the table in paragraph (a)(2), revise the entries for cattle,
liver; cattle, meat byproducts, except liver; goat, liver; goat, meat
byproducts, except liver; horse, liver; horse, meat byproducts, except
liver; sheep, liver; and sheep, meat byproducts, except liver.
The revised texts read as follows:
Sec. 180.649 Saflufenacil; tolerances for residues.
(a) * * * (1) * * *
------------------------------------------------------------------------
Parts per
Commodity million
------------------------------------------------------------------------
Almond, hulls.............................................. 0.10
Cotton, gin byproducts..................................... 0.45
Cottonseed subgroup 20C.................................... 0.20
Fruit, citrus, group 10.................................... 0.03
Fruit, pome, group 11...................................... 0.03
Fruit, stone, group 12..................................... 0.03
Grain, aspirated fractions................................. 10
Grain, cereal, forage, fodder and straw group 16........... 0.10
Grain, cereal, group 15.................................... 0.03
Grape...................................................... 0.03
Nut, tree, group 14........................................ 0.03
Pea and bean, dried shelled, except soybean, subgroup 6C... 0.30
Pea and bean, succulent shelled, subgroup 6B............... 0.03
Pea, hay................................................... 17
Pistachio.................................................. 0.03
Rapeseed subgroup 20A...................................... 0.45
Sunflower subgroup 20B..................................... 1.0
Soybean, hulls............................................. 0.50
Soybean, seed.............................................. 0.10
Vegetable, foliage of legume, group 7 (except pea, hay).... 0.10
Vegetable, legume, edible podded, subgroup 6A.............. 0.03
------------------------------------------------------------------------
(2) * * *
------------------------------------------------------------------------
Parts per
Commodity million
------------------------------------------------------------------------
* * * * *
Cattle, liver.............................................. 2.5
* * * * *
Cattle, meat byproducts, except liver...................... 0.05
* * * * *
Goat, liver................................................ 2.5
* * * * *
Goat, meat byproducts, except liver........................ 0.05
* * * * *
Horse, liver............................................... 2.5
* * * * *
Horse, meat byproducts, except liver....................... 0.05
* * * * *
Sheep, liver............................................... 2.5
* * * * *
Sheep, meat byproducts, except liver....................... 0.05
* * * * *
------------------------------------------------------------------------
* * * * *
[FR Doc. 2011-11553 Filed 5-10-11; 8:45 am]
BILLING CODE 6560-50-P